FDA Reclassification of Rapid Antigen Flu Testing

 

FDA reclassification of rapid flu antigen testing

Please join Frederick S. Nolte, Ph.D., D(ABMM), F(AAM), Professor and Vice Chair for Laboratory Medicine in the Department of Pathology and Laboratory Medicine, and Medical Director of Clinical Laboratories, Molecular Pathology Laboratory and Point-Care-Testing at the Medical University of South Carolina, as he shares his insight regarding the recent FDA reclassification of Rapid Antigen flu testing, and why it's an opportunity for lab leadership.

 

Previous Article
Critical Traits to Look for in a POC Director
Critical Traits to Look for in a POC Director

As the need for point of care testing grows, it’s more critical than ever before to implement and run a suc...

Next Article
Why Forward-Thinking Lab Leaders Are Investing in Whole-Genome Sequencing
Why Forward-Thinking Lab Leaders Are Investing in Whole-Genome Sequencing

Whole genome sequencing has changed the way we understand the human genome. Discover why lab leaders are in...